Crtac1B Monoclonal Antibody for Selective Fragment Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies struggle to specifically measure Crtac1B and its fragments in biological samples due to the similarity in amino acid sequences between Crtac1A and Crtac1B, leading to inaccurate detection and interference from Crtac1A.
Innovation Solution
Development of a monoclonal antibody with specific CDR sequences (SEQ ID NOs: 1-5) that binds selectively to Crtac1B and its fragments, along with a reagent kit and method for immunoassays to quantify Crtac1B in samples like blood, plasma, and cerebrospinal fluid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing antibody technologies are used to measure Crtac1B, then general detection capability is achieved, but measurement precision deteriorates due to sequence similarity between Crtac1A and Crtac1B causing cross-reactivity
Solution Approach 1:
The monoclonal antibody is designed to recognize a specific local region (amino acid residues 607-612) of Crtac1B that differs from Crtac1A. By targeting this unique local sequence, the antibody achieves high specificity for Crtac1B while ignoring the similar Crtac1A protein, thereby eliminating cross-reactivity and improving measurement precision.
2Reliability
If existing antibody technologies are used to measure Crtac1B, then detection capability is achieved, but reliability deteriorates due to inability to specifically distinguish Crtac1B from Crtac1A
Solution Approach 1:
The antibody targets the unique amino acid sequence at positions 607-612 of Crtac1B, which differs from Crtac1A. This localized recognition ensures that the antibody reliably binds only to Crtac1B and its fragments containing this region, eliminating cross-reactivity with Crtac1A and improving both reliability and measurement precision.
3Measurement precision
If conventional measurement methods are used, then general protein detection is achieved, but measurement precision deteriorates due to presence of Crtac1B fragments with varying sequences
Solution Approach 1:
The monoclonal antibody recognizes a specific local region (amino acid residues 607-612) that is conserved across Crtac1B and its fragments. This localized recognition allows the antibody to bind to full-length Crtac1B and various fragments containing this region, achieving consistent and precise detection despite sequence variability in other regions of the fragments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody enables precise detection of Crtac1B and its fragments, reducing interference from Crtac1A and enhancing measurement accuracy in biological samples.
Implementation Method 1
an isolated monoclonal antibody having a heavy chain and a light chain, wherein the heavy chain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 3
Data Source
AI summary
An object of the present invention to provide a monoclonal antibody that specifically binds to Crtac1B and/or a fragment thereof, a reagent and a reagent kit for measuring Crtac1B containing the antibody, and a method for measuring Crtac1B using the antibody. The present invention provides an isolated monoclonal antibody, wherein the heavy chain including a CDR1 including the amino acid sequence of SEQ ID NO: 1, a CDR2 including the amino acid sequence of SEQ ID NO: 2, and a CDR3 including the amino acid sequence of SEQ ID NO: 3, and the light chain comprises a CDR1 including the amino acid sequence of SEQ ID NO: 4, a CDR2 including the amino acid sequence KAS, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 5.